Compliance With Annex 1: Sterile Fill/Finish For Early Phase Clinical Supplies

By Joe Page, Ph.D., President of Eurofins BioPharma Product Testing San Diego

Adhering to the 2023 revision of Annex 1 is a priority for organizations managing early-phase clinical supplies, as it introduces rigorous standards for sterile fill-finish operations. At the heart of these requirements is the Contamination Control Strategy (CCS), which demands a proactive, risk-based approach to limiting microbial and endotoxin contamination. One of the most significant shifts is the move toward removing human operators from the critical zone, often through the adoption of gloveless, robotic isolator technology.

Compliance also necessitates mastering complex procedures like Pre-Use Post Sterilization Integrity Testing (PUPSIT) and implementing single-use systems to minimize cleaning-related risks. From validating hydrogen peroxide decontamination cycles to utilizing press-cap technology that eliminates particulate generation, every detail must be documented and tested.